Back to results
US 2022/0401535 A1Published application
Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
OwnerJonathan C. Kagan, Dania Zhivakiinventors
Life of this patent
Estimating the term…
Abstract
The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy.
Claims21
A method of generating a population of therapeutic dendritic cells, the method comprising:
- obtaining living dendritic cells from a cell donor;
- priming the dendritic cells with a TLR ligand ex vivo;
- culturing the primed dendritic cells with a non-canonical inflammasome-activating lipid ex vivo;
- and
- loading the dendritic cells with an immunogen, thereby generating a population of therapeutic dendritic cells.
2 more elements
A method of inducing an immune response in a subject, comprising:
- obtaining living dendritic cells from a cell donor;
- priming the dendritic cells with a TLR ligand ex vivo;
- culturing the primed dendritic cells with a non-canonical inflammasome-activating lipid ex vivo;
- loading the dendritic cells with an immunogen, thereby generating a population of therapeutic dendritic cells;
- and
- administering the living dendritic cells to the subject, thereby inducing an immune response in a subject.
3 more elements
A method of treating cancer in a subject, comprising:
- obtaining living dendritic cells from a cell donor;
- priming the dendritic cells with a TLR ligand ex vivo;
- culturing the primed dendritic cells with a non-canonical inflammasome-activating lipid ex vivo;
- loading the dendritic cells with an immunogen, thereby generating a population of therapeutic dendritic cells;
- and
- administering the living dendritic cells to the subject, thereby treating cancer in a subject.
3 more elements
Dependencies are inferred from the claim text.